13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK-1308-001

    Acronym: 

    MK-1308-001

    ACTRN/NCT /ethics: 

    NCT03179436

    Scientific title: 

    A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab forsubjects with advanced solid tumours

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Solid tumours
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2017-07-02
    Molecular Target Anticipated End Date 2022-10-24
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid tumours
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2017-07-02
    Anticipated End Date 2022-10-24

    Trial Summary

    This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.

    Lay Summary

    A Phase 1 open-label, multi-arm, multicentre study of MK-1308 in combination with pembrolizumab forsubjects with advanced solid tumours

    Sponsor / Cooperative group

    Merck

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Brian Stein Recruiting